Nautilus Biotechnology, Inc.
NASDAQ:NAUTBiotechnology
+$0.05 today
- Market cap
- $300.60M
- Beta
- 0.75
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$0.45
Volume 3.95M
Average 0.40M
Returns on capital
Nautilus Biotechnology, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-37.6%
avg 1550.4%
ROIC
-35.7%
avg -34.7%
ROA
-30.9%
avg 31.2%
Analysis
ROA is currently the strongest return metric at -30.9% versus its period average of 31.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Sujal Patel | Co-Founder, Chief Executive Officer, President, Secretary & Director | USD 763.58K | 51 | — | — |
Anna Mowry | Chief Financial Officer & Treasurer | USD 551.2K | 43 | 160.00K | 0.13% |
Parag Mallick | Co-Founder, Chief Scientist & Director | USD 535.5K | 48 | 280.00K | 0.22% |
Gwen E. Weld | Chief People Officer | USD 390.97K | 68 | 160.00K | 0.13% |
Matthew Murphy ESQ. | General Counsel | USD 382.65K | 61 | — | — |
Subra Sankar | Senior Vice President of Product Development | USD 38.47K | 66 | — | — |
Amber Faust | Vice President of Global Sales | — | — | — | — |
Jamie Rose Kuhar | Vice President of Marketing | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Mar 2, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$65,237.50
Sells
2
$11.75M
Net Transaction Value
−$11.68M
Net selling
Most Active
AH Equity Partners Bio II, L.L.C.
2 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Jun 2, 26Jun 2, 2026 | AH Equity Partners Bio II, L.L.C. Indirect | Sell | $10.8M$10,847,538.90 |
| Jun 2, 26Jun 2, 2026 | AH Equity Partners Bio II, L.L.C. Indirect | Sell | $902.5K$902,461.10 |
| Mar 4, 26Mar 4, 2026 | Patel Sujal M Direct | Buy | $65.2K$65,237.50 |
Summary
Insiders reported 1 buys worth $65,237.50 and 2 sells worth $11.75M over the last 12 months. That adds up to net selling of $11.68M. AH Equity Partners Bio II, L.L.C. was the most active insider with 2 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Nautilus Biotechnology, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about NAUT's management, answered from reported figures.
Who manages NAUT?
Nautilus Biotechnology, Inc. (NAUT) lists 8 active executives. The top listed executive is Parag Mallick, Co-Founder, Chief Scientist & Director.
Are NAUT insiders buying or selling?
Recent insider activity shows net buying of $70.88M.
Continue the stock analysis
Jump to another research area for this company.